Gaeta G, Lupoli S, Brancaccio V, Effuso L, Russo V, Boccalatte A
Divisione di Cardiologia, Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli, Napoli.
Cardiologia. 1998 Jul;43(7):731-5.
The relationship between anticardiolipin antibodies (aCL) and acute myocardial infarction (AMI) is still controversial. The purpose of this study was to investigate the prevalence of aCL in young patients (age < or = 45 years) with AMI; record the aCL titre during different days of disease; assess the relationship between aCL titres and in-hospital myocardial infarction complications. The aCL were measured in 108 consecutive patients and in 31 controls (ELISA method). High aCL levels (IgG or IgM) were found in 19/108 (17.6%) patients and 5/31 (16.1%) controls (NS); aCL titres were similar in different days after AMI and did not differ in controls and in patients with or without early myocardial infarction complications. In conclusion, the aCL levels are not elevated in AMI patients, do not change during the early stage of the disease and are not associated with in-hospital complications.
抗心磷脂抗体（aCL）与急性心肌梗死（AMI）之间的关系仍存在争议。本研究的目的是调查年轻（年龄≤45岁）AMI患者中aCL的患病率；记录疾病不同时期的aCL滴度；评估aCL滴度与院内心肌梗死并发症之间的关系。采用酶联免疫吸附测定法（ELISA法）对108例连续的患者及31例对照者进行aCL检测。在108例患者中有19例（17.6%）、31例对照者中有5例（16.1%）检测到高水平的aCL（IgG或IgM）（无显著性差异）；AMI后不同时期的aCL滴度相似，有或无早期心肌梗死并发症的患者与对照者之间的aCL滴度也无差异。总之，AMI患者的aCL水平未升高，在疾病早期不发生变化，且与院内并发症无关。
